Press & Media

Syneos joins with physIQ, InCarda on atrial fibrillation study

Written by physIQ | August 30, 2022

Originally published in Outsourcing Pharma

The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.

Read more here